期刊文献+

双色FISH分析浸润性乳腺癌HER-2基因扩增模式

HER-2 Amplification Pattern in Invasive Breast Cancer by Dual Color FISH
原文传递
导出
摘要 [目的]应用荧光原位杂交技术(FISH)分析乳腺癌HER-2基因状态。[方法]采用双色FISH技术检测100例浸润性乳腺癌HER-2基因,分析FISH和免疫组织化学(IHC)检测结果,分析17号染色体多倍体比率及其与HER-2基因扩增的关系。[结果]100例浸润性乳腺癌标本中,HER-2蛋白IHC3+21例者中FISH检测均为阳性;IHC2+69例者中FISH检测为阳性的占72%,IHC1+10例者FISH检测为阳性的占20%。17号染色体多倍体的比率为51%。17号染色体二倍体与多倍体标本中,HER-2基因扩增的比率分别是76%和69%,差异无统计学意义(P=0.330)。[结论]乳腺癌IHC检测HER-2为1+~2+者需进一步行FISH检测确定HER-2基因状态;应用双色FISH方法能准确、全面评估HER-2基因状态。
机构地区 辽宁省肿瘤医院
出处 《中国肿瘤》 CAS 2012年第3期225-229,共5页 China Cancer
  • 相关文献

参考文献9

  • 1Bartlett J,Munro A,Dunn J,et al.Predictive markers of anthracycline benefit:a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial(NEAT/BR9601)[J].Lancet Oncol,2010,11(3):266-274.
  • 2Marchio C,Lambros MB,Gugliotta P,et al.Does chromo-some17centromere copy number predict polysomy in breast cancer?A fluore scence in situ hybridization and microarray-based CGH analysis[J].J Pathol,2009,219(1):16-24.
  • 3Vranic S,Teruya B,Repertinger S,et al.Assessment of HER2gene status in breast carcinomas with polysomy of chromosome17[J].Cancer,2011,117(1):48-53.
  • 4Jones C,Ford E,Gillett C,et al.Molecular cytogenetic i-dentification of subgroups of gradeⅢinvasive ductal breast carcinomas with different clinical outcomes[J].Clin Cancer Res,2004,10(18):5988-5997.
  • 5Abdel-Fatah TM,Powe DG,Hodi Z,et al.High frequency of coexistence of columnar cell lesions,lobular neoplasia,and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma[J].Am J Surg Pathol,2007,31(3):417-426.
  • 6Perez EA,Roche PC,Jenkins RB,et al.HER2testing in patients with breast cancer:poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization[J].Mayo Clin Proc,2002,77(2):148-154.
  • 7Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science,1987,235(4785):177-182.
  • 8Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1659-1672.
  • 9Slamon DJ,Leyland-Jones B,Shak S,et al.Addition of HerceptinTM(humanized anti-HER2antibody)to first line chemotherapy for HER2 over expressing metastatic breast cancer(HER2+/MBC)markedly increases anticancer ac-tivity:a randomized,multinational controlled phaseⅢtrial[J].J Clin Oncol,1998,16:abstr377.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部